How much funding has IconOVir Bio raised?

IconOVir Bio has raised $97.2M in total funding, most recently a Venture Round.

Who are IconOVir Bio's investors?

IconOVir Bio's investors include Vida Ventures, Nextech Invest, Two River Group, Bellco Capital, Polaris Partners, GV.

When was IconOVir Bio founded?

IconOVir Bio was founded in 2018.

Where is IconOVir Bio headquartered?

IconOVir Bio is headquartered in San Diego, California, United States.

What industry is IconOVir Bio in?

IconOVir Bio operates in Biotech, Drug Discovery, Therapeutics.

How many employees does IconOVir Bio have?

IconOVir Bio has 11-50 employees.

IconOVir Bio

Next-generation oncolytic virus therapies for solid tumors.

San Diego, United States · Founded 2018 · $97.2M raised

Biotech

Drug Discovery

Therapeutics

Headquarters: San Diego, California
Employees: 11–50
Founded: 2018
Business Model: B2B

Website: iconovir.com
Total Funding: $97.2M
Last Round: $20.2M Venture RoundJun 2024
Rounds: 2

About

IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy for the treatment of cancer. Its proprietary oncolytic virus platform is based on technology developed by scientific founder Clodagh O'Shea, Ph.D., of the Salk Institute, and is designed to selectively replicate within and destroy tumor cells while sparing normal tissue. The company was founded by Two River Group, chaired by Arie Belldegrun, M.D., FACS — the team behind Kite Pharma and Allogene Therapeutics — and is focused on developing next-generation oncolytic viruses engineered for superior potency and immune engagement in solid tumors.

Summary

IconOVir Bio is a Biotech company based in San Diego, United States, founded in 2018. It has raised $97.2M in total across 2 rounds, most recently a $20.2M Venture Round round in Jun 2024. Investors include Vida Ventures, Nextech Invest and Two River Group.